A Phase 1 interventional study of AR882 Single Dose and AR882 Multiple Dose in Renal Impairment, sponsored by Arthrosi Therapeutics. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-05.
Sponsored by Arthrosi Therapeutics (part of Swedish Orphan Biovitrum) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.
Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 157th largest by enrollment of the 468 interventional ones that give a count, is one of 22 that started in 2021, is one of 232 in phase 1, and was the 434th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.
Browse Renal Insufficiency studies →40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–80 · Healthy volunteers
Sanofi · Sites in United States
Ages 18–75 · Healthy volunteers
Hoffmann-La Roche · Sites in United States
Ages 18–85 · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United States
Ages 18–80 · Healthy volunteers
Kailera · Sites in United States
Ages 18–85 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
553 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 247 · Phase 2 71 · Phase 3 53 · Phase 4 44
First in 1990; this study’s year is marked. 22 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is above the median of 40 across 1,060 interventional studies indexed under Renal Insufficiency.
Median enrollment 32 across the 468 interventional studies, 182 across the 82 observational. Of the 464 that completed or were terminated, 169 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
334 of 553 have an industry lead sponsor. The 10 most frequent:
This study is registered under Arthrosi Therapeutics, one of the names counted as Swedish Orphan Biovitrum. Under that name alone:
Arthrosi Therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Swedish Orphan Biovitrum has 1 study filed under Renal Insufficiency — fewer than ten, so there is no comparison to draw.
22 of the studies in Renal Insufficiency with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT07341516Paris Translational Research Center for Organ TransplantationWorldwide Assessment of Deceased Donor Kidney Utilization | 2026-11 |
| NCT04605679Loma Linda UniversityHepatitis C Virus (HCV) Positive Kidney Grafts in HCV Negative Recipients | 2026-12 |
| NCT07857837ShionogiStudy of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls | 2026-12-04 |
| NCT03099434Johns Hopkins UniversityExpanding Live Donor Kidney Transplantation Through Advocacy Training and Social Media | 2026-12-07 |
Add all 22 to your calendar (.ics) → With an account.
Among the 553 studies in Renal Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 2-segment, multi-center, phase 1, open-label, study evaluating the pharmacokinetics and pharmacodynamics of AR882 in subjects with various degrees of renal impairment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Subjects:
Renal Impaired Subjects:
Exclusion Criteria:
All Subjects:
Renal Impaired Subjects:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with various degrees of renal impairment
Drug: AR882 Single Dose · Drug: AR882 Multiple Dose
Subjects with normal renal function
Drug: AR882 Single Dose · Drug: AR882 Multiple Dose
A single dose of AR882
AR882 taken once daily for 14 days
Area under the curve (AUC) for plasma following a single dose of AR882 in subjects with renal impairment and normal renal function
Time frame: 6 days
Time to maximum plasma concentration (Tmax) following a single dose of AR882 in subjects with renal impairment and normal renal function
Time frame: 6 days
Maximum plasma concentration (Cmax) following a single dose of AR882 in subjects with renal impairment and normal renal function
Time frame: 6 days
Terminal half-life (t 1/2) following a single dose of AR882 in subjects with renal impairment and normal renal function
Time frame: 6 days
Amount excreted (Ae) into urine following a single dose of AR882 in subjects with renal impairment and normal renal function
Time frame: 6 days
Renal clearance (CLr) following a single dose of AR882 in subjects with renal impairment and normal renal function
Time frame: 6 days
AUC for plasma following multiple doses of AR882 in subjects with renal impairment and normal renal function
Time frame: 15 days
Tmax following multiple doses of AR882 in subjects with renal impairment and normal renal function
Time frame: 15 days
Cmax following multiple doses of AR882 in subjects with renal impairment and normal renal function
Time frame: 15 days
t 1/2 following multiple doses of AR882 in subjects with renal impairment and normal renal function
Time frame: 15 days
Incidence of Adverse Events, changes in laboratory, electrocardiogram, and vital signs following a single dose of AR882 in subjects with renal impairment and normal renal function
Time frame: 14 days
Incidence of Adverse Events, changes in laboratory, electrocardiogram, and vital signs following multiple doses of AR882 in subjects with renal impairment and normal renal function
Time frame: 21 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2021 to primary completion in Jun 2022, 17 months.
Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 17 months is above that.
Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AR882